Bemnifosbuvir-Ruzasvir for Hepatitis C
Recruiting at 10 trial locations
CT
Overseen ByClinical Trials Administrator
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Recruiting
Sponsor: Atea Pharmaceuticals, Inc.
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Eligibility Criteria
This trial is for adults with chronic Hepatitis C Virus (HCV) who are also on stable antiretroviral therapy for HIV, have a CD4 T-cell count over 200 cells/mm3, undetectable HIV-1 RNA levels, and no previous treatments with direct-acting antivirals. Participants must not have severe liver cirrhosis and women able to bear children must use effective contraception.Inclusion Criteria
Key
I have never been treated with drugs specifically for hepatitis C.
I have a history of chronic hepatitis C.
See 4 more
Treatment Details
Interventions
- Bemnifosbuvir-Ruzasvir (BEM/RZR) (Anti-viral)
- Sofosbuvir-Velpatasvir (SOF/VEL) (Anti-viral)
Trial OverviewThe study compares two drug combinations for treating chronic HCV: Bemnifosbuvir-Ruzasvir (BEM/RZR) versus Sofosbuvir-Velpatasvir (SOF/VEL). The goal is to determine which treatment is more effective and safer for patients.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Bemnifosbuvir-Ruzasvir (BEM/RZR)Experimental Treatment1 Intervention
Group II: Sofosbuvir-Velpatasvir (SOF/VEL)Active Control1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Atea Pharmaceuticals, Inc.
Lead Sponsor
Trials
29
Recruited
4,600+